# Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

> **NCT00357461** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** gp100:209-217(210M) peptide vaccine
- **BIOLOGICAL:** gp100:280-288(288V) peptide vaccine
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** ipilimumab

## Key facts

- **NCT ID:** NCT00357461
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00357461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00357461, "Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00357461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*